Organization
Bristol-Myers Squibb, Princeton, United States
9 abstracts
Abstract
ABATACEPT IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF A PHASE II STUDY Org: Altoona Center for Clinical Research, Duncansville, United States, New England Research Associates, LLC, Trumbull, Bristol-Myers Squibb, Princeton, United States, University of Klinische Immunologie, Hamburg, Germany,
Abstract
ANTI-CITRULLINATED PEPTIDE ANTIBODIES AND RHEUMATOID FACTOR TESTING PATTERNS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS IN THE US Org: Bristol-Myers Squibb, Princeton, United States,
Abstract
ABATACEPT INDUCES SUSTAINED IMPROVEMENTS IN PHYSICAL FUNCTION AND REDUCTIONS IN PAIN OVER 3 YEARS IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO METHOTREXATEOrg: University of Alberta Hospital, Edmonton, Canada, The Center for Rheumatology, Albany, United States, Centro Medico Nacional, Mexico City, Mexico, Bristol-Myers Squibb, Princeton, United States, University of Alabama at Birmingham School of Medicine, Birmingham, United States,
Abstract
A PHASE IIB STUDY OF THE EFFICACY AND SAFETY OF SUBCUTANEOUS CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL ANTIBODY) WITH OR WITHOUT METHOTREXATE IN ADULTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE Org: Brigham and Women's Hospital, Boston, MA, Swedish Medical Center and University of Washington, Seattle, United States, Organizaciόn Medica de Investigaciόn, Buenos Aires, Argentina, Keio University, Tokyo, Japan, Csolnoky Ferenc Hospital, Veszprém, Hungary,
Abstract
ANTI-CCP IS AN INDEPENDENT PREDICTOR OF 12-MONTH EULAR RESPONSE IN PATIENTS WITH RA TREATED WITH ABATACEPT Org: Sint Maartenskliniek and Radboud UMC, Radboud UMC, Sint Maartenskliniek, Nijmegen, Netherlands, Bristol-Myers Squibb, Uxbridge, United Kingdom, Bristol-Myers Squibb, Princeton, United States,
Abstract
ABATACEPT AND ANTI-TNF MONOCLONAL ANTIBODIES: EFFICACY AND SAFETY COMPARISONS Org: University of Colorado, Denver, United States, Hôpital Cochin, Descartes University, Paris, France, University of Texas Southwestern Medical Center, Dallas, TX, Bristol-Myers Squibb, Princeton, United States,
Abstract
ABATACEPT SHOWS BETTER SUSTAINABILITY THAN TNF INHIBITORS WHEN USED FOLLOWING INITIAL BIOLOGIC DMARD FAILURE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: 8 YEARS OF REAL-WORLD OBSERVATIONS FROM THE RHUMADATA® CLINICAL DATABASE AND REGISTRY Org: Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, Rheumatology, Centre d'ostéoporose et de rhumatologie de Québec (CORQ), Québec, Canada, Bristol-Myers Squibb, Princeton, United States, Bristol-Myers Squibb, Montréal, Canada, Bristol-Myers Squibb, Uxbridge, United Kingdom,
Abstract
ABATACEPT REDUCES FATIGUE AND PAIN SEVERITY AND SLEEP PROBLEMS THROUGH 2 YEARS IN RHEUMATOID ARTHRITIS PATIENTS IN THE AIM AND ATTAIN TRIALSOrg: Bristol-Myers Squibb, Princeton, United States, Center for Rheumatology, Immunology and Arthritis, Fort Lauderdale, Bristol-Myers Squibb, Mumbai,
Abstract
ASSOCIATION BETWEEN CONVERSION TO ACPA/RF SERONEGATIVE STATUS AND CLINICAL OUTCOMES FOLLOWING TREATMENT WITH ABATACEPT IN COMBINATION WITH METHOTREXATE COMPARED WITH METHOTREXATE ALONE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS AND POOR PROGNOSTIC INDICOrg: Bristol-Myers Squibb, Rueil-Malmaison, France, Bristol-Myers Squibb, Princeton, United States,